Sebetralstat: A Rapidly Acting Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema

• Egile Nagusiak: Edward P. Feener (Egilea), Rebecca L. Davie (Egilea), Nivetha Murugesan (Egilea), Stephen J. Pethen (Egilea), Sally L. Hampton (Egilea), Michael D. Smith (Egilea), Paul K. Audhya (Egilea), Chris M. Yea (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2024-04-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Sebetralstat is a novel, potent, and selective oral plasma kallikrein inhibitor drug candidate in clinical development for the on-demand treatment of hereditary angioedema (HAE). Upon binding, sebetralstat induces a conformational change in the active site of plasma kallikrein, which contributes to...